Related Experiment Videos
Phase I study of pentamethylmelamine.
Cancer Treatment Reports
|January 1, 1980
Summary
Pentamethylmelamine, a hexamethylmelamine derivative, showed similar tumor activity but caused severe side effects in cancer patients. Its potential utility is questionable due to significant central nervous system toxicity and myelosuppression.
Area of Science:
- Oncology
- Pharmacology
- Clinical Cancer Research
Background:
- Hexamethylmelamine (HMM) is an antineoplastic agent.
- Pentamethylmelamine (PMM) is a soluble derivative of HMM.
- PMM exhibits comparable efficacy to HMM in preclinical tumor models.
Purpose of the Study:
- To evaluate the clinical activity and toxicity of pentamethylmelamine (PMM) in patients with advanced cancer.
- To assess the safety profile of PMM, including central nervous system (CNS) effects and myelosuppression.
Main Methods:
- Intravenous (IV) administration of PMM at a dose of 1200 mg/m2.
- Monitoring for adverse events, including gastrointestinal, psychotropic, and neurological effects.
- Evaluation of hematological parameters to assess myelosuppression over 10 consecutive days.
Main Results:
- PMM administration resulted in severe nausea, vomiting, and significant psychotropic effects.
- Electroencephalogram (EEG) changes were observed in patients treated with PMM.
- Marked but reversible myelosuppression occurred with prolonged PMM administration (10 days).
Conclusions:
- The severe CNS toxicity observed at myelosuppressive doses limits the therapeutic potential of pentamethylmelamine.
- Pentamethylmelamine's clinical utility is questionable due to its adverse effect profile.
- Further investigation into dose modification or alternative administration schedules may be warranted, but significant challenges remain.